Nebulized Recombinant Tissue Plasminogen Activator (rt-PA) for Acute COVID-19-Induced Respiratory Failure: An Exploratory Proof-of-Concept Trial

Pratima Chowdary, Banwari Agarwal, Maria Rita Peralta, Sanjay Bhagani, Simon Lee, James Goldring, Marc Lipman, Emal Waqif, Mark Phillips, Helen Philippou, Jonathan H. Foley, Nicola J. Mutch, Robert A.s. Ariëns, Kathleen A. Stringer, Federico Ricciardi, Marie Watissée, Derralynn Hughes, Amit Nathwani, Anne Riddell, David Patch, Jim Buckley, Mark De Neef, Rahul Dimber, Cecilia Diaz-Garcia, Honey Patel, Aarti Nandani, Upuli Dissanayake, Nick Chadwick, Ahmed Abdelaal Ahmed Mahmoud, Peter Watkinson, Eamon Raith, Suveer Singh, Tony Wolff, Rajeev Jha, Simon Brill, Ameet Bakhai, Alison Evans, Farhat Gilani, Keith GomezJournal of Clinical Medicine 2023 · DOI

TL;DR

This study explores nebulized recombinant tissue plasminogen activator (rt-PA) as a potential treatment for acute respiratory failure in COVID-19 patients. The proof-of-concept trial found nebulized rt-PA to be safe, well-tolerated, and showed a trend towards improved oxygenation, particularly in patients on non-invasive respiratory support.

What Problem Does This Paper Address?

Severe COVID-19 often leads to acute lung injury (ALI) and acute respiratory distress syndrome (ARDS), characterized by diffuse alveolar damage and the formation of fibrin clots within the lungs. This fibrin deposition disrupts the alveolar-capillary barrier, impairing gas exchange and leading to respiratory failure. Standard treatments focus on inflammation, but the role of localized fibrin clots in driving disease severity and mortality is significant. Existing fibrinolytic therapies, like intravenous rt-PA, carry a high risk of systemic bleeding. This paper investigates whether delivering rt-PA directly to the lungs via nebulization can effectively break down these localized clots and improve oxygenation without the systemic bleeding risks.

Methods

This was an exploratory, proof-of-concept safety and efficacy study conducted in two cohorts (C1 and C2) of adults with COVID-19-induced respiratory failure requiring respiratory support.

  • Nebulized rt-PA Administration: Patients received nebulized rt-PA (Alteplase) via an Aerogen nebulizer, alongside standard of care.
  • Dosing Strategy: An initial dosing regimen was established in C1, which was then refined based on safety and efficacy observations for use in C2. Dosing was adjusted based on ventilation type (invasive mechanical ventilation - IMV, or non-invasive respiratory support - NIRS) and treatment duration was capped at 14 days. Treatment was discontinued if fibrinogen levels dropped below a certain threshold or if the patient no longer required oxygen.
  • Control Group: In C1, a matched historical control (MHC) group receiving standard of care was used for efficacy comparison. In C2, all patients received rt-PA with standard of care.
  • Safety Endpoints: Co-primary safety endpoints included treatment-related bleeds and significant decreases in fibrinogen levels.
  • Efficacy Endpoints: The primary efficacy endpoint was the change in the PaO2/FiO2 (P/F) ratio from baseline to study end. Secondary endpoints included clinical status, oxygen-free days, and ventilator-free days.
  • Biomarker Analysis: Exploratory analysis of fibrinolysis biomarkers was conducted to assess systemic absorption.

Datasets

The study utilized data from patients admitted to the Royal Free London NHS Foundation Trust.

  • Cohort 1 (C1): 9 patients received nebulized rt-PA with standard of care. 18 matched historical controls (MHC) were used for comparison.
  • Cohort 2 (C2): 26 patients received nebulized rt-PA with standard of care.

The study did not introduce new benchmarks but used historical controls for comparison in C1.

Key Insights and Ideas

  • Targeted Thrombolysis: The core idea is that by delivering rt-PA directly to the lungs, it can target fibrin deposits in the alveoli without causing widespread systemic bleeding, a major limitation of intravenous fibrinolysis.
  • Feasible Safety Profile: The study successfully demonstrated that nebulized rt-PA can be administered safely, with no severe bleeding events directly attributable to the drug and no significant decreases in systemic fibrinogen. This is crucial for a therapy targeting a critical illness like COVID-19.
  • Oxygenation Improvement Trend: While not statistically significant in all comparisons due to sample size, there was a notable trend towards improved oxygenation (P/F ratio) in patients treated with nebulized rt-PA, particularly in the NIRS group. This suggests the therapy might be effective in improving gas exchange.
  • NIRS Patients Showed Greater Benefit: The NIRS group in Cohort 2 demonstrated a larger improvement in P/F ratio and required fewer treatment days compared to the IMV group, hinting that nebulized rt-PA might be more beneficial for patients not yet requiring invasive ventilation.

Key Results

  • Safety: Seven bleeding events were reported in Cohort 1 (4 patients), all categorized as mild or moderate and resolved completely. None were deemed related to rt-PA. In Cohort 2, 25 bleeding events were reported, with four considered possibly related to rt-PA (one severe, three mild). No patients experienced pulmonary hemorrhage or clinically significant decreases in systemic fibrinogen.
  • Efficacy (P/F Ratio): In Cohort 1, the rt-PA group showed a greater improvement in mean P/F ratio from baseline to study end (154 to 299) compared to the MHC group (154 to 212). In Cohort 2, NIRS patients showed a larger improvement in P/F ratio (126 to 240) compared to IMV patients (120 to 188).
  • Treatment Duration: Patients in Cohort 2 on NIRS required fewer treatment days (7.86) compared to those on IMV (10.5).
  • Mortality: In Cohort 1, only one patient (11.1%) in the rt-PA group died, compared to ten (55.6%) in the MHC group. In Cohort 2, mortality was 41.7% for IMV patients and 21.4% for NIRS patients.

Limitations and Future Work

The authors acknowledge several limitations:

  • Study Design: The study was a proof-of-concept, exploratory trial with a small sample size, particularly in Cohort 1. The use of historical controls in C1 introduces potential biases.
  • Heterogeneity: The NIRS group was heterogeneous in terms of devices used, and the methods for calculating P/F ratios differed between IMV and NIRS patients.
  • Blinding: The study was not blinded, which could introduce bias.
  • Concomitant Treatments: The rapid evolution of standard of care during the pandemic meant that patients received varying concomitant treatments (e.g., steroids, immunomodulators), which could have influenced outcomes.
  • Drug Delivery Challenges: Delivering nebulized rt-PA to NIRS patients presented practical challenges, including difficulty maintaining oxygen support, drug loss in circuits, and issues with mouthpiece administration.

Future Work: The authors emphasize the need for larger, randomized clinical trials to definitively demonstrate the clinical significance and magnitude of benefit from nebulized rt-PA. Further research is also recommended to better understand the specific role of alveolar fibrin in COVID-19 and to optimize drug delivery methods for non-invasive respiratory support.

Summary updated

Abstract

Acute lung injury in COVID-19 results in diffuse alveolar damage with disruption of the alveolar-capillary barrier, coagulation activation, alveolar fibrin deposition and pulmonary capillary thrombi. Nebulized recombinant tissue plasminogen activator (rt-PA) has the potential to facilitate localized thrombolysis in the alveolar compartment and improve oxygenation. In this proof-of-concept safety study, adults with COVID-19-induced respiratory failure and a <300 mmHg PaO<sub>2</sub>/FiO<sub>2</sub> (P/F) ratio requiring invasive mechanical ventilation (IMV) or non-invasive respiratory support (NIRS) received nebulized rt-PA in two cohorts (C1 and C2), alongside standard of care, between 23 April-30 July 2020 and 21 January-19 February 2021, respectively. Matched historical controls (MHC; n = 18) were used in C1 to explore efficacy. Safety co-primary endpoints were treatment-related bleeds and <1.0-1.5 g/L fibrinogen reduction. A variable dosing strategy with clinical efficacy endpoint and minimal safety concerns was determined in C1 for use in C2; patients were stratified by ventilation type to receive 40-60 mg rt-PA daily for ≤14 days. Nine patients in C1 (IMV, 6/9; NIRS, 3/9) and 26 in C2 (IMV, 12/26; NIRS, 14/26) received nebulized rt-PA for a mean (SD) of 6.7 (4.6) and 9.1(4.6) days, respectively. Four bleeds (one severe, three mild) in three patients were considered treatment related. There were no significant fibrinogen reductions. Greater improvements in mean P/F ratio from baseline to study end were observed in C1 compared with MHC (C1; 154 to 299 vs. MHC; 154 to 212). In C2, there was no difference in the baseline P/F ratio of NIRS and IMV patients. However, a larger improvement in the P/F ratio occurred in NIRS patients (NIRS; 126 to 240 vs. IMV; 120 to 188) and fewer treatment days were required (NIRS; 7.86 vs. IMV; 10.5). Nebulized rt-PA appears to be well-tolerated, with a trend towards improved oxygenation, particularly in the NIRS group. Randomized clinical trials are required to demonstrate the clinical effect significance and magnitude.
BibTeX
@article{chowdary2023nebulized,
  author = {Pratima Chowdary and Banwari Agarwal and Maria Rita Peralta and Sanjay Bhagani and Simon Lee and James Goldring and Marc Lipman and Emal Waqif and Mark Phillips and Helen Philippou and Jonathan H. Foley and Nicola J. Mutch and Robert A.S. Ariëns and Kathleen A. Stringer and Federico Ricciardi and Marie Watissée and Derralynn Hughes and Amit Nathwani and Anne Riddell and David Patch and Jim Buckley and Mark De Neef and Rahul Dimber and Cecilia Diaz-Garcia and Honey Patel and Aarti Nandani and Upuli Dissanayake and Nick Chadwick and Ahmed Abdelaal Ahmed Mahmoud and Peter Watkinson and Eamon Raith and Suveer Singh and Tony Wolff and Rajeev Jha and Simon Brill and Ameet Bakhai and Alison Evans and Farhat Gilani and Keith Gomez},
  title = {{Nebulized Recombinant Tissue Plasminogen Activator (rt-PA) for Acute COVID-19-Induced Respiratory Failure: An Exploratory Proof-of-Concept Trial}},
  journal = {Journal of Clinical Medicine},
  year = {2023},
  doi = {10.3390/jcm12185848},
}
Figure